

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



WUXI APPTEC CO., LTD.*
無錫藥明康德新藥開發股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 2359)

DELAY IN DESPATCH OF CIRCULAR

Reference is made to the announcement of WuXi AppTec Co., Ltd.* (無錫藥明康德新藥開發股份有限公司) (the “**Company**”) dated July 21, 2020 in relation to, among other things, (i) the proposed adoption of the H Share Award and Trust Scheme; and (ii) the proposed grant of Awards to the Connected Selected Participants under the H Share Award and Trust Scheme (the “**Announcement**”). Unless otherwise defined, capitalized terms used herein shall have the same meanings as those defined in the Announcement.

As disclosed in the Announcement, a circular of the Company (the “**Circular**”) containing, among other things, (i) further details of the Scheme; (ii) further details of the proposed grant of Awards to the Connected Selected Participants; (iii) a letter of recommendation from the Independent Financial Adviser; (iv) a letter of recommendation from the Independent Board Committee; and (v) a notice convening the EGM, is expected to be despatched to the Shareholders on or before July 31, 2020.

As additional time is required to prepare and finalize certain information to be included in the Circular, it is expected that the despatch date of the Circular will be postponed to a date falling on or before August 14, 2020.

By order of the Board
WuXi AppTec Co., Ltd.*
Dr. Ge Li
Chairman

Hong Kong, July 31, 2020

As of the date of this announcement, the Board comprises Dr. Ge Li, Mr. Edward Hu, Dr. Steve Qing Yang, Mr. Zhaohui Zhang and Dr. Ning Zhao as executive Directors, Mr. Xiaomeng Tong and Dr. Yibing Wu as non-executive Directors and Dr. Jiangnan Cai, Ms. Yan Liu, Mr. Dai Feng, Dr. Hetong Lou and Mr. Xiaotong Zhang as independent non-executive Directors.

* For identification purposes only